Hansa Biopharma AB (publ) (STO:HNSA) Analysts Just Slashed This Year's Revenue Estimates By 11%
Jul 23
Swedish (OMX) Biotech Industry Analysis
UpdatedAug 06, 2024
DataAggregated Company Financials
Companies64
- 7D-5.9%
- 3M-1.4%
- 1Y13.3%
- YTD-1.5%
Over the last 7 days, the Biotech industry has dropped 5.9%, driven by a pullback from Swedish Orphan Biovitrum of 4.2%. Meanwhile, Isofol Medical actually outperformed within the industry, gaining 37% in the last week. Over the past 12 months, the industry was up 13%. As for the next few years, earnings are expected to grow by 47% per annum.
Industry Valuation and Performance
Has the Swedish Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 06 Aug 2024 | SEK 186.1b | SEK 31.4b | -SEK 5,420,584,602.86 | 41.8x | -34.3x | 5.9x |
| Thu, 04 Jul 2024 | SEK 191.7b | SEK 30.6b | -SEK 5,537,333,555.67 | 38.4x | -34.6x | 6.3x |
| Sat, 01 Jun 2024 | SEK 198.4b | SEK 30.6b | -SEK 5,725,690,180.58 | 39.8x | -34.7x | 6.5x |
| Mon, 29 Apr 2024 | SEK 183.9b | SEK 30.8b | -SEK 5,612,153,350.26 | 50.9x | -32.8x | 6x |
| Wed, 27 Mar 2024 | SEK 185.9b | SEK 29.8b | -SEK 5,637,426,016.82 | 61.5x | -33x | 6.2x |
| Fri, 23 Feb 2024 | SEK 182.1b | SEK 29.7b | -SEK 5,686,647,248.71 | 52.7x | -32x | 6.1x |
| Sun, 21 Jan 2024 | SEK 186.9b | SEK 28.7b | -SEK 1,200,602,862.00 | 57.4x | -155.6x | 6.5x |
| Tue, 19 Dec 2023 | SEK 180.9b | SEK 28.7b | -SEK 1,169,941,500.00 | 59.7x | -154.7x | 6.3x |
| Thu, 16 Nov 2023 | SEK 166.4b | SEK 28.7b | -SEK 1,230,832,373.00 | 51.2x | -135.2x | 5.8x |
| Sat, 14 Oct 2023 | SEK 154.5b | SEK 27.4b | -SEK 1,962,955,624.00 | 48.8x | -78.7x | 5.6x |
| Mon, 11 Sep 2023 | SEK 150.4b | SEK 27.4b | -SEK 1,977,547,540.00 | 47x | -76.1x | 5.5x |
| Wed, 09 Aug 2023 | SEK 155.6b | SEK 27.5b | -SEK 1,576,205,416.00 | 53.3x | -98.7x | 5.6x |
| Fri, 07 Jul 2023 | SEK 160.4b | SEK 26.4b | -SEK 1,278,793,132.00 | 46.6x | -125.4x | 6.1x |
| Sun, 04 Jun 2023 | SEK 168.1b | SEK 26.4b | -SEK 1,242,510,092.00 | 45.5x | -135.3x | 6.4x |
| Tue, 02 May 2023 | SEK 175.9b | SEK 26.3b | -SEK 1,248,453,450.00 | 45.6x | -140.9x | 6.7x |
| Thu, 30 Mar 2023 | SEK 166.5b | SEK 25.4b | -SEK 2,016,640,714.00 | 38.4x | -82.6x | 6.6x |
| Sat, 25 Feb 2023 | SEK 170.0b | SEK 25.4b | -SEK 2,041,715,401.00 | 39.6x | -83.3x | 6.7x |
| Mon, 23 Jan 2023 | SEK 176.8b | SEK 23.8b | -SEK 1,839,311,016.00 | 32.2x | -96.1x | 7.4x |
| Wed, 21 Dec 2022 | SEK 159.1b | SEK 23.8b | -SEK 1,839,194,697.00 | 31.8x | -86.5x | 6.7x |
| Fri, 18 Nov 2022 | SEK 157.2b | SEK 23.9b | -SEK 1,807,539,360.00 | 32.4x | -87x | 6.6x |
| Sun, 16 Oct 2022 | SEK 153.0b | SEK 22.9b | -SEK 3,333,771,163.00 | 31.2x | -45.9x | 6.7x |
| Tue, 13 Sep 2022 | SEK 158.7b | SEK 22.9b | -SEK 3,245,854,870.00 | 33.9x | -48.9x | 6.9x |
| Thu, 11 Aug 2022 | SEK 171.2b | SEK 22.7b | -SEK 3,505,517,539.00 | 34.9x | -48.8x | 7.5x |
| Sat, 09 Jul 2022 | SEK 164.2b | SEK 21.4b | -SEK 3,520,210,178.00 | 40.3x | -46.7x | 7.7x |
| Mon, 06 Jun 2022 | SEK 158.7b | SEK 21.4b | -SEK 3,525,318,201.00 | 44.4x | -45x | 7.4x |
| Wed, 04 May 2022 | SEK 150.6b | SEK 21.3b | -SEK 3,496,052,570.00 | 45.9x | -43.1x | 7.1x |
| Fri, 01 Apr 2022 | SEK 172.2b | SEK 19.7b | -SEK 3,159,874,686.00 | 51x | -54.5x | 8.7x |
| Sun, 27 Feb 2022 | SEK 159.5b | SEK 19.6b | -SEK 2,877,018,904.00 | 49.6x | -55.4x | 8.1x |
| Tue, 25 Jan 2022 | SEK 160.7b | SEK 19.1b | -SEK 2,042,162,885.00 | 48.2x | -78.7x | 8.4x |
| Thu, 23 Dec 2021 | SEK 198.1b | SEK 19.1b | -SEK 2,003,682,605.00 | 53x | -98.9x | 10.4x |
| Sat, 20 Nov 2021 | SEK 202.8b | SEK 19.0b | -SEK 1,412,764,251.00 | 55x | -143.5x | 10.7x |
| Mon, 18 Oct 2021 | SEK 200.0b | SEK 18.1b | -SEK 1,345,754,716.00 | 47.3x | -148.7x | 11.1x |
| Wed, 15 Sep 2021 | SEK 215.7b | SEK 18.1b | -SEK 1,339,275,285.95 | 53.4x | -161x | 11.9x |
| Fri, 13 Aug 2021 | SEK 193.4b | SEK 18.1b | -SEK 1,175,418,285.95 | 53.6x | -164.5x | 10.7x |
Price to Earnings Ratio
-164.5x
Current Industry PE
- Investors are pessimistic on the Swedish Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 7.3x is higher than the industry's current PS ratio of 5.9x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Meanwhile revenues for these companies have grown 20% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Trends
Which industries have driven the changes within the Swedish Healthcare industry?
| SE Market | -6.69% | |
| Healthcare | -6.08% | |
| Biotech | -5.91% | |
| Biotech | -5.91% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ISOFOL Isofol Medical | SEK 2.67 | 36.9% +SEK 116.3m | 325.2% | PB3.8x | |
| ALZ Alzinova | SEK 3.64 | 41.1% +SEK 47.2m | 6.9% | PS9x | |
| LIPUM Lipum | SEK 11.30 | 5.6% +SEK 12.7m | 26.7% | PS4522.7x | |
| BIOSGN Biosergen | SEK 0.65 | 13.3% +SEK 10.8m | -32.7% | PB4.3x | |
| MODTX Modus Therapeutics Holding | SEK 1.82 | 14.1% +SEK 8.1m | -20.2% | PB4.5x |